CANDEL THERAPEUTICS APPOINTS PHARMA VETERAN AND IMMUNOLOGIST PAUL-PETER TAK, M.D., PH.D., AS CHIEF EXECUTIVE OFFICER; EXPANDS LEADERSHIP TEAM WITH CHIEF FINANCIAL OFFICER, CHIEF BUSINESS OFFICER AND CHIEF REGULATORY OFFICER APPOINTMENTS
– Advancing oncolytic viral immunotherapies that light up and destroy local tumors, while creating a durable and systemic immune response – Phase 3 prostate cancer program enrolling patients, clinical data readouts from other ongoing clinical programs in 2021 – Company founder and former CEO Estuardo Aguilar-Cordova, M.D. inf., Ph.D., takes on role of chief scientific officer – Nathan Caffo named chief business officer; John Canepa appointed as chief financial officer; Susan Stewart named chief regulatory officer